State Key Laboratory of Experimental Hematology and National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020, China.
Center for Stem Cell Medicine and Department of Stem Cell & Regenerative Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, 300020, China.
Sci China Life Sci. 2021 Oct;64(10):1634-1644. doi: 10.1007/s11427-020-1880-y. Epub 2021 Feb 4.
The blood and immune system of coronavirus disease 2019 (COVID-19) infected patients are dysfunctional, and numerous studies have been conducted to resolve their characteristics and pathogenic mechanisms. Nevertheless, the variations of immune responses along with disease severity have not been comprehensively documented. Here, we profiled the single-cell transcriptomes of 96,313 peripheral blood mononuclear cells (PBMCs) derived from 12 COVID-19 patients (including four moderate, four severe and four critical cases) and three healthy donors. We showed that proliferative CD8 effector T cells with declined immune functions and cytotoxicity accumulated in the critical stage. By contrast, the quantity of natural killer (NK) cells was significantly reduced, while they exhibited enhanced immune activities. Notably, a gradually attenuated responseto COVID-19 along with disease severity was observed in monocytes, in terms of cellular composition, transcriptional discrepancy and transcription factor regulatory network. Furthermore, we identified immune cell-type dependent cytokine signatures distinguishing the severity of COVID-19 patients. In addition, cell interactions between CD8 effector T/NK cells and monocytes mediated by inflammatory cytokines were enhanced in moderate and severe stages, but weakened in critical cases. Collectively, our work uncovers the cellular and molecular players underlying the disordered and heterogeneous immune responses associated with COVID-19 severity, which could provide valuable insights for the treatment of critical COVID-19 patients.
新型冠状病毒病 2019(COVID-19)感染患者的血液和免疫系统功能失调,许多研究旨在阐明其特征和发病机制。然而,免疫反应随疾病严重程度的变化尚未得到全面记录。在这里,我们对 12 名 COVID-19 患者(包括 4 名中度、4 名重度和 4 名危重症患者)和 3 名健康供体的 96313 个外周血单个核细胞(PBMC)的单细胞转录组进行了分析。结果表明,在危重症阶段,增殖的 CD8 效应 T 细胞功能下降,细胞毒性增强。相比之下,NK 细胞数量显著减少,但免疫活性增强。值得注意的是,单核细胞的组成、转录差异和转录因子调控网络显示,随着疾病严重程度的增加,对 COVID-19 的反应逐渐减弱。此外,我们还确定了依赖于免疫细胞类型的细胞因子特征,可区分 COVID-19 患者的严重程度。此外,在中度和重度阶段,CD8 效应 T/NK 细胞与单核细胞之间由炎症细胞因子介导的细胞相互作用增强,但在危重症病例中减弱。总之,本研究揭示了与 COVID-19 严重程度相关的失调和异质性免疫反应的细胞和分子基础,可为治疗危重症 COVID-19 患者提供有价值的见解。